27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- The FDA has granted priority review status to Amryt Pharma's (NASDAQ:AMYT) marketing application seeking approval for Oleogel-S10 to treat Epidermolysis Bullosa (EB).
- Oleogel-S10 is a potential treatment for the cutaneous manifestations of Junctional and Dystrophic EB, a rare genetic skin disorder characterized by blistering lesions on the skin and mucous membranes.
- In general, the FDA's Priority Review designation accelerates the review time from ten months to a goal of six months from the date of acceptance of the filing.
- The FDA has set a target action date of November 30.
- Oleogel-S10 had previously received Fast Track Designation and Rare Pediatric Disease Designation from the FDA. If the NDA for Oleogel-S10 is approved, the company will apply for a priority review voucher.
- "Confirmation of a target PDUFA date of November 30 keeps us on track for potential approval this year," said CEO Joe Wiley.
- Yesterday, the FDA accepted for review the company's Oleogel-S10 marketing application. The agency had informed that notification of any filing review issues, including priority review determination and target action date, would be provided by June 12.
- Related content: Benzinga's Full FDA Calendar.
- Price Action: AMYT shares closed at $11.65 on Wednesday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!